Harris Rotman - Jun 14, 2023 Form 3 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
SVP Regulatory Affairs
Signature
/s/ Gregory Weinhoff, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Jun 14, 2023
Transactions value $
$0
Form type
3
Date filed
6/23/2023, 05:01 PM
Next filing
Sep 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CNTA Ordinary Shares 33.5K Jun 14, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CNTA Share Option (right to buy) Jun 14, 2023 Ordinary Shares 125K $4.47 Direct F1, F3
holding CNTA Share Option (right to buy) Jun 14, 2023 Ordinary Shares 49.9K $3.85 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The shares reported were issued pursuant to a Restricted Share Unit ("RSU") grant issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 1, 2024.
F3 25% of the shares subject to such option shall vest and become exercisable on August 1, 2023 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
F4 6,234 of the shares vest and become exercisable on August 1, 2023 and 1/48th of the shares subject to such option shall vest and become exercisable in 42 monthly installments on the first day of each month thereafter.

Remarks:

Exhibit 24 - Power of Attorney